GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes

Pregnancy, breastfeeding, certain thyroid-cancer histories, severe digestive conditions, and some medication combinations may make GLP-1 treatment unsuitable
Unlock the potential of your research with IGF-1 LR3
Archived from the original (PDF) on 11 February 2014
At Spa Blue in Orlando, FL, our highly trained providers specialize in personalized wellness solutions, including Vitamin B12 supplements and injections designed to boost your energy, metabolism, and overall vitality